NewLink Genetics (NLNK) Tops Q4 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
NewLink Genetics Provides Operational Update and Reports Fourth Quarter, Year End 2015 Financial Results
February 29, 2016 8:02 AM ESTNewLink Genetics Outlines 2016 Business Priorities to Support Development of Immuno-Oncology Product Pipeline
Management to Host Conference Call and Webcast Today at 8:30 a.m. ET
AMES, Iowa, Feb. 29, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates, including both cellular immunotherapy and checkpoint inhibitor programs, to improve the lives of patients with cancer, today reported business highlights and consolidated financial results for the fourth quarter and year ended 2015. NewLink Genetics also outlined key... More
